LENZ Therapeutics Inc Market Cap ($108.71 Million)
Market Cap & Net Worth: LENZ Therapeutics Inc (LENZ)
LENZ Therapeutics Inc market cap. LENZ Therapeutics Inc (NASDAQ:LENZ) has a market capitalization of $108.71 Million ($108.71 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18701 globally and #4348 in its home market, demonstrating a 9.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LENZ Therapeutics Inc's stock price $3.46 by its total outstanding shares 31420343 (31.42 Million). Also see cash flow conversion of LENZ Therapeutics Inc for how efficiently the company converts equity into cash flow.
LENZ Therapeutics Inc Market Cap History (2021–2026)
LENZ Therapeutics Inc market cap history from 2021 to 2026. Data shows change from $264.05 Million to $108.71 Million (-21.30% CAGR). Check current stock price of LENZ Therapeutics Inc for real-time trading data and today's change.
Index Memberships
LENZ Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #516 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1794 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.01% | #235 of 263 |
Weight: LENZ Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LENZ Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LENZ Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LENZ Therapeutics Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
26.34x
LENZ Therapeutics Inc's market cap is 26.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $70.53 Million | $15.00 Million | -$10.81 Million | 4.70x | N/A |
| 2025 | $502.73 Million | $19.09 Million | -$82.13 Million | 26.34x | N/A |
Competitor Companies of LENZ by Market Capitalization
Companies near LENZ Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see LENZ total asset value for a full breakdown of the balance sheet.
Key companies related to LENZ Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of LENZ Therapeutics Inc (2021–2026)
Market capitalization of LENZ Therapeutics Inc from 2021 to today. Between 2021 and today, LENZ Therapeutics Inc's market cap moved from $264.05 Million to $ 108.71 Million, with a yearly change of -21.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $108.71 Million | -78.38% |
| 2025 | $502.73 Million | -45.83% |
| 2024 | $927.97 Million | +1567.27% |
| 2023 | $55.66 Million | -21.09% |
| 2022 | $70.53 Million | -73.29% |
| 2021 | $264.05 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of LENZ Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.71 Million USD |
| MoneyControl | $108.71 Million USD |
| MarketWatch | $108.71 Million USD |
| marketcap.company | $108.71 Million USD |
| Reuters | $108.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more